# Hybrid Ablation of Atrial Fibrillation in Heart Failure

Study · id `cardio:ct-nct05411614` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05411614](<https://clinicaltrials.gov/study/NCT05411614>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05411614

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems; Heart failure  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 120 participants.

## Technical summary

Registry record NCT05411614. Randomized; single masking; primary purpose treatment. Start 2022-06-25 (actual); primary completion 2026-05 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT05411614, source copy `cardio:ctgov-nct05411614-2025-11-28`, retrieved 2026-10-26)
- Started: 2022-06-25 (actual) (ClinicalTrials.gov record NCT05411614, source copy `cardio:ctgov-nct05411614-2025-11-28`, retrieved 2026-10-26)
- Primary completion: 2026-05 (anticipated) (ClinicalTrials.gov record NCT05411614, source copy `cardio:ctgov-nct05411614-2025-11-28`, retrieved 2026-10-26)
- Completion: 2027-10 (anticipated) (ClinicalTrials.gov record NCT05411614, source copy `cardio:ctgov-nct05411614-2025-11-28`, retrieved 2026-10-26)
- Countries: United Kingdom (ClinicalTrials.gov record NCT05411614, source copy `cardio:ctgov-nct05411614-2025-11-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05411614-2025-11-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: Hybrid Ablation of Atrial Fibrillation in Heart Failure
- Acronym: HALT AF
- Condition: Persistent Atrial Fibrillation
- Condition: Atrial Fibrillation, Persistent
- Condition: Atrial Arrhythmia
- Condition: Atrial Fibrillation
- Condition: Heart Failure
- Condition: Left Ventricular (LV) Systolic Dysfunction
- Intervention (Device): AtriCure EPi-Sense-AF Guided Coagulation System +/- Atriclip
- Intervention (Device): Endocardial Catheter Ablation
- Lead sponsor: St. George's Hospital, London
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)

## Provenance

Content hash: e9ff1274083408093142ed18a44db8a965cc6a63832ff719562b26303d43d6c6
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
